Patents Assigned to Monash University
  • Patent number: 10673095
    Abstract: Electrolytes and electrochemical cells include a novel ionic liquid having a quaternary cation and a boron cluster anion. In some versions, the boron cluster anion will be a functionalized or unfunctionalized icosahedral boranyl or carboranyl anion. Electrochemical cells have an electrolyte including the ionic liquid. In some versions, the ionic liquid is used as a solvent to dissolve an ionic shuttle salt for transport of active material, with an optional co-solvent. Methods to synthesize the ionic liquid include contacting a boron cluster salt with a quaternary salt to form the ionic liquid by a metathesis reaction.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: June 2, 2020
    Assignees: Toyota Motor Engineering & Manufacturing North America, Inc., Monash University
    Inventors: Rana Mohtadi, Oscar Tutusaus, Douglas R. MacFarlane, Mega Kar
  • Patent number: 10672933
    Abstract: A new approach to graphene-enabled plasmonic resonant structures in the THz is demonstrated in a hybrid graphene-metal design in which the graphene acts as a gate-tunable inductor, and metal acts as a capacitive reservoir for charge accumulation. A large resonant absorption in graphene can be achieved using the metal-graphene plasmonic scheme, and the peak can approach 100% in an optimized device, ideal for graphene-based THz detectors. Using high mobility graphene (?>50000 cm2V?1s?1) will allow anomalously high resonant THz transmission (near 100%) through ultra-subwavelength graphene-filled metallic apertures at a resonance frequency that is gate tunable. This metal-graphene plasmonic scheme enables near perfect tunable THz filter or modulator.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: June 2, 2020
    Assignees: University of Maryland, College Park, The Government of the United States of America, as represented by The Secretary Of The Navy, Monash University
    Inventors: Mohammad M. Jadidi, Andrei B. Sushkov, David Kurt Gaskill, Michael Fuhrer, Howard Dennis Drew, Thomas E. Murphy
  • Patent number: 10653632
    Abstract: The present disclosure relates generally to binder powders for use in powder material processing and processes for their preparation. The disclosure further relates to binder powders for use in making solid powder compact forms, solid powder compact forms containing said binder powders and methods for making solid powder compact forms.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: May 19, 2020
    Assignee: Monash University
    Inventors: David Morton, Laurence Orlando, Tony Qi Zhou, Louise Chia-Hua Ho
  • Patent number: 10621882
    Abstract: A process for cognitive assessment and training, the process being executed by at least one processor of a computing system and including the steps of: receiving interaction data representing interactions between an application executing on an electronic device and an individual interacting with the executing application; processing the interaction data to generate performance data representing quantitative measures of the performance of the individual with respect to the executing application; and processing the performance data for the individual to generate cognitive assessment data indicative of at least one attention-related ability of the individual.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: April 14, 2020
    Assignees: TALI Health Pty Ltd, Monash University
    Inventors: Andrew Somers, Grace Lethlean, Hannah Kirk, Kim Cornish
  • Patent number: 10501487
    Abstract: Provided herein are organobismuth (III) phosphinate complexes, which comprise a phosphinate group and an aromatic carbocyclyl or aromatic heterocyclyl group. The complexes find use as antibacterial agents, and accordingly also provided herein are products, devices, compositions and materials comprising the complexes, for example medical products such as wound dressings and bandages.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: December 10, 2019
    Assignee: MONASH UNIVERSITY
    Inventors: Philip Andrews, Melissa Werrett, Madleen Busse
  • Patent number: 10485847
    Abstract: The invention relates to disulfide-rich peptides derived from spider venom and their use, particularly as neuroprotective agents. The invention also relates to nucleic acid molecules encoding the peptides as well as constructs and host cells comprising those nucleic acid molecules.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: November 26, 2019
    Assignees: THE UNIVERSITY OF QUEENSLAND, MONASH UNIVERSITY
    Inventors: Glenn Frederick King, Lachlan Douglas Rash, Irene Chassagnon, Sandy Steffany Pineda Gonzalez, Robert Edward Widdop, Claudia Ann Ireland
  • Patent number: 10458914
    Abstract: The invention described herein relates to a method of detecting malaria comprising the steps of: (i) delivering an evanescent IR beam through said ATR substrate in contact with a patient blood sample; (ii) detecting IR radiation transmitted from the ATR substrate to produce a signal characteristic for one or more lipids in the sample, and (iii) processing said signal and a set of reference library spectra of lipids associated with malaria parasites in order to detect matches and quantify said one or more lipids in the sample. In contrast to the prior art, the present invention relies on detecting lipids instead of hemozoin.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: October 29, 2019
    Assignees: Monash University, University of Melbourne
    Inventors: Bayden Robert Wood, Aazam Khoshmanesh, Matthew Dixon, Leann Tilley, Donald McNaughton
  • Patent number: 10459257
    Abstract: A spaser device comprises a graphene resonator and a carbon nanotube (CNT) gain element coupled via exciton-plasmon interaction. The graphene resonator may be a rectangular or square graphene nanoflake (GNF), and the CNT gain element may be characterized by chirality vector (n,m) selected such that the CNT has semiconducting properties. The CNT gain element may be illuminated using a light source having a photon energy corresponding with a first exciton energy (E22) of the CNT, whereby excitons having a second exciton energy (E11) less than the first exciton energy are generated in the CNT, and coupled to a surface plasmon (SP) mode of the graphene resonator. When the rate of generation of excitons having the second exciton energy exceeds a gain threshold, continuous spasing is established within the spaser device.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: October 29, 2019
    Assignee: Monash University
    Inventors: Chanaka Rupasinghe, Malin Premaratne, Ivan D. Rukhlenko
  • Publication number: 20190320928
    Abstract: A neural event process, including receiving a neural response signal, decomposing the signal using at least one wavelet, differentiating phase data of the wavelets and the response signal to determine maxima and minima of the phase data and the signal, and processing the maxima and minima to determine peaks representing neural events.
    Type: Application
    Filed: July 1, 2019
    Publication date: October 24, 2019
    Applicant: MONASH UNIVERSITY
    Inventor: Brian John LITHGOW
  • Publication number: 20190316116
    Abstract: The invention relates to a highly stable polypeptide scaffold comprising an amino acid sequence based on a fibronectin type III (Fn3) domain and a polypeptide comprising the scaffold with grafted loops. The invention also relates to a nucleic acid molecule encoding the polypeptide scaffold, a method of making the polypeptide scaffold, and a composition comprising the polypeptide scaffold.
    Type: Application
    Filed: December 15, 2015
    Publication date: October 17, 2019
    Applicant: MONASH UNIVERSITY
    Inventors: Benjamin POREBSKI, Ashley BUCKLE
  • Publication number: 20190307811
    Abstract: The present disclosure teaches a method for treating airways disease including ameliorating symptoms of airway inflammation, airway remodeling and airway hyper-responsiveness. The method comprises the administration of an anti-fibrotic agent together with amnion epithelial cells or their functional equivalents or exosomes.
    Type: Application
    Filed: August 4, 2017
    Publication date: October 10, 2019
    Applicants: HUDSON INSTITUTE OF MEDICAL RESEARCH, HUDSON INSTITUTE OF MEDICAL RESEARCH, MONASH UNIVERSITY, MONASH UNIVERSITY
    Inventors: Chrishan Surendran SAMUEL, Rebecca Seok Wai LIM
  • Patent number: 10426598
    Abstract: A visual image processing method is based on received spatial field information (302) from a spatial field sensor (116). A data store (804) is accessed, which contains a sensor map data structure (206) comprising a set of predefined regions (208) within a spatial field corresponding with the information received via the sensor input. Each predefined region is associated in the data structure with one or more of a set of stimuli (204) applicable to a biological visual system, and each stimulus corresponds with a visual percept (210). The spatial field information associated with each region is processed to generate stimulus control information which is applied to select, from within the sensor map data structure, stimuli from the set of stimuli for application to the biological visual system. Output stimulus signals (310) are generated, which are suitable for application to the biological visual system based upon the selected stimuli.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: October 1, 2019
    Assignee: Monash University
    Inventor: Wai Ho Li
  • Publication number: 20190269718
    Abstract: The present invention relates to a method of adversely affecting a biofilm, the method comprising exposing the biofilm to a composition comprising an effective amount of polymer that incorporates within its backbone structure a first polymerised residue of ethylenically unsaturated monomer, said first polymerised monomer residue comprising a covalently bound moiety that (i) presents pendant from the backbone structure, and (ii) comprises a cationic functional group or precursor functional group thereof.
    Type: Application
    Filed: May 13, 2019
    Publication date: September 5, 2019
    Applicants: Commonwealth Scientific and Industrial Research Organisation, Monash University
    Inventors: Katherine Elizabeth Sarah Locock, Laurence Meagher, Yue Qu, Ana Traven
  • Patent number: 10368770
    Abstract: A neural event process, including receiving a neural response signal, decomposing the signal using at least one wavelet, differentiating phase data of the wavelets and the response signal to determine maxima and minima of the phase data and the signal, and processing the maxima and minima to determine peaks representing neural events.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: August 6, 2019
    Assignee: Monash University
    Inventor: Brian John Lithgow
  • Patent number: 10328075
    Abstract: The present invention relates generally to a method of therapeutically or prophylactically treating ischaemia-induced myocardial tissue damage, in particular ischaemia-reperfusion-induced myocardial tissue damage. More particularly, the present invention relates to a method of reducing the extent of ischaemia-induced myocardial tissue damage in a mammal by selectively upregulating FPR1-mediated ERK signalling. The method of the present invention is useful, inter alia, in reducing the extent and/or severity of myocardial tissue damage associated with conditions characterized by myocardial ischaemia or myocardial ischaemia and reperfusion, such as acute myocardial infarction caused by atherosclerotic artery occlusion or blood clot-induced artery occlusion.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: June 25, 2019
    Assignees: Baker Heart and Diabetes Institute, Monash University
    Inventors: Rebecca Helen Ritchie, Cheng Xue Qin, Arthur Christopoulos, Patrick Michael Sexton, Jonathan Bayldon Baell
  • Publication number: 20190185950
    Abstract: A method for producing a soft magnetic material having both high saturation magnetization and low coercive force, including: preparing an alloy having a composition represented by Compositional Formula 1 or 2 and having an amorphous phase, and heating the alloy at a rate of temperature rise of 10° C./sec or more and holding for 0 to 80 seconds at a temperature equal to or higher than the crystallization starting temperature and lower than the temperature at which Fe—B compounds start to form wherein, Compositional Formula 1 is Fe100-x-yBxMy, M represents at least one element selected from Nb, Mo, Ta, W, Ni, Co and Sn, and x and y are in atomic percent (at %) and satisfy the relational expressions of 10?x?16 and 0?y?8, and Compositional Formula 2 is Fe100-a-b-cBaCubM?c, M? represents at least one element selected from Nb, Mo, Ta, W, Ni and Co, and a, b and c are in atomic percent (at %) and satisfy the relational expressions 10?a?16, 0<b?2 and 0?c?8.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 20, 2019
    Applicants: TOYOTA JIDOSHA KABUSHIKI KAISHA, MONASH UNIVERSITY
    Inventors: Kiyotaka ONODERA, Kiyonori SUZUKI, Richard PARSONS, Bowen ZANG
  • Publication number: 20190167615
    Abstract: The present invention relates to methods for treating or preventing or delaying the progression or onset of autoimmune disease, providing dietary metabolites comprising a combination of two or more short chain fatty acids, esters or salts thereof. The present invention also provides compositions for treating, preventing or delaying the progression of, or onset of autoimmune disease.
    Type: Application
    Filed: August 10, 2017
    Publication date: June 6, 2019
    Applicants: MONASH UNIVERSITY, COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR
    Inventors: Charles REAY MACKAY, Eliana Marino MORENO, Trevor LOCKETT, Julie CLARKE, David TOPPING
  • Patent number: 10297396
    Abstract: This present invention relates to a method of preparing graphene-based film, said method comprising: providing a first graphene-based film comprising sheets of graphene, graphene oxide, partially reduced graphene oxide, reduced graphene oxide, or a combination of two or more thereof, that are (i) arranged relative to each other in a substantially planar manner so as to form a layered structure, and (ii) at least partially separated by a liquid medium; exchanging said liquid medium with a packing density adjustment medium that comprises at least two components, wherein one of said components has a volatility greater than the other component; and removing at least some of the more volatile component from the first graphene-based film to produce a graphene-based film that has a different packing density of the graphene-based sheets relative to that of the first graphene-based film.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: May 21, 2019
    Assignee: Monash University
    Inventors: Dan Li, Xiaowei Yang
  • Patent number: 10294280
    Abstract: A fusion protein comprising an N-terminal portion and a C-terminal portion, wherein the N-terminal portion is a heterologous protein of interest which includes membrane proteins and antigens and the C-terminal portion is a polyhedrin targeting peptide which is derived from cypovirus polyhedrin and binds to cypovirus polyhedrin. The polyhedrin targeting peptide is described as a C-terminal portion of cypovirus polyhedrin and as C-terminal portion of cypovirus polyhedrin absent all or part of the N-terminal H1 helix sequence. Vectors and cells capable of expressing the fusion proteins are also provided. The fusion proteins fold with cypovirus polyhedrin to form modified complexes, polyhedra/microcubes useful in myriad applications, including as a platform technology for prophylactic or therapeutic vaccinations, therapeutics and diagnostics, including vaccines, therapeutics and diagnostics etc. employing membrane proteins.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 21, 2019
    Assignee: Monash University
    Inventor: Fasseli Joseph Coulibaly
  • Publication number: 20190145952
    Abstract: The invention principally relates to a method of detecting a disease agent in blood, comprising: (i) creating a sample infra-red spectrum representative of the blood, with one or more spectral components, each having a wavenumber and absorbance value; (ii) providing a reference database of spectral models, each model having one or more database spectral components of a wavenumber and an absorbance value, wherein the database spectral components identify disease agents; (iii) determining whether one or more database spectral components corresponds to one or more sample spectral components, and (iv) compiling a list of corresponding database components identified.
    Type: Application
    Filed: December 3, 2018
    Publication date: May 16, 2019
    Applicant: MONASH UNIVERSITY
    Inventors: Bayden R. WOOD, Phillip HERAUD, David PEREZ-GUAITA